Searchable abstracts of presentations at key conferences in endocrinology

ea0096p23 | Section | UKINETS2023

Reasons patients with carcinoid heart disease are deemed unfit for surgery: our tertiary centre experience

Douglas Sasha , Naneishvili Tamara , Yuan Mengshi , Muneeb Arshad Muhammad , Steeds Richard P

Introduction: Carcinoid heart disease (CHD) is a rare complication of neuroendocrine tumours (NETs) and carcinoid syndrome (CS). Approximately one in five patients with CS go on to develop CHD, which primarily affects the right side of the heart; leading to thickened, retracted, immobile and regurgitant cardiac valves that ultimately result in right ventricular (RV) dilatation and dysfunction 1 . Patients are referred for valve replacement if they have severe ...

ea0086p166 | Adrenal and Cardiovascular | SFEBES2022

Review of multidisciplinary perioperative management of functioning and non-functioning adrenal lesions at The University Hospital Southampton NHSFT (UHS)

Bujanova Jana , Bray Diane , Richard W Lockyer C , C Hayes Matthew , Douglas James , Crabb Simon , Chance Thomas , Al-Mrayat Ma'en

Objective: We reviewed perioperative management of patients undergoing adrenal surgery at UHS between 1/12/2020 to 1/6/2022 (19-month period) since formalisation of its regional adrenal MDT.Results: 45 adrenalectomies were performed during this period with all cases being discussed at the adrenal MDT, of which 24 (53%) were referred from peripheral hospitals. Laparoscopic surgery was performed in 35/45 (78%) (median length of stay (LOS): 3d), open in 10/...

ea0090ep39 | Adrenal and Cardiovascular Endocrinology | ECE2023

“Adrenal Giants” Review of adrenal masses ≥ 10 cm detected and treated during a 10- year period at the University Hospital Southampton NHS Foundation Trust, United Kingdom

Galides Chloe , Hayes Matthew , Douglas James , W C Richard , crabb Simon , Chance Thomas , King Alexander , Al-Mrayat Ma'en , Bujanova Jana

Introduction: The aim of this project was to review all adrenal masses ≥ 10 cm managed in our organisation over a 10-year period (2012-2022).Results: 20 adrenal masses ≥10 cm in maximal diameter were identified (range 10-32 cm, average 16.6 cm, 6 above 20 cm and one above 30 cm). Age at presentation was 17-80 y (mean 56.3 y, 50% F). Duration of symptoms: 1 day-18 months, mean 7.5 months with 6 presenting acutely. Follow-up period: 1 month-122...

ea0063p669 | Interdisciplinary Endocrinology 1 | ECE2019

Dyslipidaemia and altered hepatic function in males - consequences of androgen excess in fetal life

Siemienowicz Katarzyna , Filis Panagiotis , Shaw Sophie , Douglas Alex , Thomas Jennifer , Howie Forbes , Fowler Paul , Duncan Colin , Rae Mick

Introduction: Adult male offspring of women with PCOS have increased dyslipidaemia, characterised by elevated triglycerides (TG), increased total and LDL-cholesterol (LDL-C), and hyperinsulinaemia. As altered intrauterine endocrine environments can ‘programme’ adverse health outcomes in adulthood we hypothesised that this dyslipidaemia was a consequence of a hyperandrogenic intrauterine environment. We used an outbred large animal model to identify if prenatal androg...

ea0063p1009 | Interdisciplinary Endocrinology 2 | ECE2019

Decreased hepatic detoxification potential in males - consequences of androgen excess in fetal life

Siemienowicz Katarzyna , Filis Panagiotis , Shaw Sophie , Douglas Alex , Thomas Jennifer , Howie Forbes , Fowler Paul , Duncan Colin , Rae Mick

Introduction: Altered intrauterine endocrine environments can ‘programme’ adverse health outcomes. Linkage between altered androgen exposure in utero and adverse offspring health is robust. For example, increased maternal androgen concentrations and PCOS in female offspring and dyslipidaemia in male offspring. We hypothesised that the liver was a major target for androgenic programming in utero and hepatic dysfunction would be present in offspring. ...

ea0026pl2 | Making sense with thyroid hormone | ECE2011

Making sense with thyroid hormone

Forrest Douglas , Cordas Emily , Fu Yulong , Liu Hong , Lu Ailing , Ma Michelle , Ng Lily , Peeters Robin , Sharlin David

Thyroid hormone has long been known as a key developmental factor in human and model species. Insufficient thyroid hormone during development can impair the growth and maturation of diverse tissue and organ systems. One of the most serious risks associated with congenital hypothyroidism is defective brain maturation and mental retardation. However, in recent years, targeted mutagenesis of the thyroid hormone receptor genes in model species has expanded our understanding of the...

ea0013p219 | AMEND Young Investigator's Award | SFEBES2007

Testicular teratoma, testicular seminoma and papillary thyroid carcinoma occurring in a single individual: a report of two unrelated cases

Syed Akheel A , Jones Nigel AG , Roberts J Trevor , Mallick Ujjal K , Douglas Fiona , Perros Petros , Quinton Richard

We describe two unrelated men with a previously unreported combination of tumours. The first patient developed a right-sided testicular teratoma at the age of 25 years treated with orchidectomy. He went on to develop a left-sided seminoma at the age of 35 years, treated with orchidectomy followed by prophylactic para-aortic radiotherapy (30 Gy in 15 fractions). At the age of 48 years he developed a nodule in the left lobe of thyroid (AC4/Thy4 on FNA) treated with hemithyroidec...

ea0092op-12-01 | Oral Session 12: Emerging Insights into Thyroid Cancer Genetics | ETA2023

Prospective evaluation of thyrospec molecular testing of indeterminate thyroid nodule cytologies following diagnostic pathway optimization

Stewardson Paul , Eszlinger Markus , Wu Jiahui , Khalil Moosa , J Demetrick Douglas , Cheung Winson , Box Adrian , Paschke Ralf

Objectives: Molecular diagnostic tests for indeterminate thyroid nodules (ITNs) are marketed based on negative predictive value (NPV) and benign call rate. Arguments that unnecessary surgeries are avoided based on NPV/BCR incorrectly assume that all ITNs would undergo diagnostic surgery in the absence of molecular testing. In our practice with centralized triage and cytopathology the resection and malignancy rate, respectively, were 21% and 26% for AUS/FLUS and 56% and 43% for...

ea0092ps3-24-05 | Thyroid Eye Disease | ETA2023

Teprotumumab for the treatment of recalcitrant thyroid eye disease

Men Clara , Amarikwa Linus , Sears Connie , Shinder Roman , Clauss Kevin , Ugradar Shoaib , Cockerham Kimberly , Wester Sara , Douglas Raymond , Kossler Andrea

Introduction: The initial clinical trials for teprotumumab excluded patients with previous orbital irradiation, surgery, glucocorticoid use (cumulative dose > 1gm), or biologic treatment. Therefore, information on the use of teprotumumab for patients who failed prior therapy is limited. Our purpose is to characterize the efficacy of teprotumumab for the treatment of recalcitrant TED.Methods: This is a multicenter retrospective study of all patients t...

ea0094p353 | Metabolism, Obesity and Diabetes | SFEBES2023

Ex-vivo immune responses of blood cells with autologous stem cell derived beta cells in Type 1 Diabetes: a pilot study

Mukhtar Ghazel , Raju Paul Susan , C Leite Nayara , Valine Laura , Reeves Patrick , A Melton Douglas , C Poznansky Mark

Introduction: Type 1 Diabetes Mellitus (T1DM) causes autoimmune destruction of insulin producing b-cells, affecting approximately 8.4 million individuals worldwide. Autologous stem cell derived b cell (sc-b cell) transplantation is a promising treatment, however receipient immunological responses remain a challenge. This pilot study utilised mass cytometry (CyTOF) to assess immune responses in co-cultures of peripheral blood mononuclear cells (PBMC) with autol...